Jiangxi Fushine Pharmaceutical Co., Ltd.
SZSE:300497.SZ
10.05 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,609.67 | 1,647.263 | 1,429.543 | 1,492.953 | 1,354.047 | 1,163.434 | 958.15 | 763.687 | 579.743 | 510.727 | 442.842 | 360.321 | 291.367 |
| Cost of Revenue
| 1,438.617 | 1,350.161 | 993.555 | 889.238 | 770.342 | 730.018 | 592.162 | 437.211 | 374.084 | 371.269 | 328.057 | 267.297 | 209.109 |
| Gross Profit
| 171.053 | 297.103 | 435.988 | 603.715 | 583.705 | 433.416 | 365.989 | 326.476 | 205.66 | 139.458 | 114.785 | 93.023 | 82.259 |
| Gross Profit Ratio
| 0.106 | 0.18 | 0.305 | 0.404 | 0.431 | 0.373 | 0.382 | 0.427 | 0.355 | 0.273 | 0.259 | 0.258 | 0.282 |
| Reseach & Development Expenses
| 97.453 | 77.45 | 78.512 | 76.527 | 59.456 | 52.877 | 43.509 | 30.901 | 18.331 | 17.866 | 13.992 | 13.111 | 0 |
| General & Administrative Expenses
| 46.866 | 42.753 | 36.68 | 31.331 | 29.629 | 25.055 | 24.272 | 23.272 | 15.851 | 10.217 | 8.09 | 6.454 | 29.647 |
| Selling & Marketing Expenses
| 35.34 | 34.212 | 34.5 | 20.841 | 27.485 | 25.299 | 18.282 | 18.321 | 15.493 | 15.848 | 12.209 | 9.921 | 9.776 |
| SG&A
| 82.206 | 76.965 | 71.179 | 52.172 | 57.115 | 50.354 | 42.554 | 41.593 | 31.344 | 26.065 | 20.299 | 16.375 | 39.423 |
| Other Expenses
| -3.782 | -87.534 | -85.985 | -8.181 | -10.906 | -4.085 | 3.468 | 19.489 | 3.82 | 3.098 | 5.677 | 6.214 | 5.986 |
| Operating Expenses
| 302.997 | 259.411 | 229.769 | 170.297 | 173.895 | 177.93 | 154.443 | 141.592 | 84.198 | 69.702 | 56.368 | 43.532 | 40.407 |
| Operating Income
| -229.389 | -133.955 | 57.004 | 386.992 | 369.264 | 231.161 | 197.585 | 188.542 | 109.903 | 60.833 | 47.484 | 40.9 | 36.805 |
| Operating Income Ratio
| -0.143 | -0.081 | 0.04 | 0.259 | 0.273 | 0.199 | 0.206 | 0.247 | 0.19 | 0.119 | 0.107 | 0.114 | 0.126 |
| Total Other Income Expenses Net
| -3.782 | -8.752 | -1.936 | -8.181 | -10.906 | -4.085 | 3.468 | 15.087 | 1.682 | 2.769 | 5.442 | 5.843 | 5.465 |
| Income Before Tax
| -233.171 | -142.707 | 55.068 | 378.811 | 358.358 | 227.077 | 201.053 | 203.629 | 111.585 | 63.602 | 52.926 | 46.743 | 42.271 |
| Income Before Tax Ratio
| -0.145 | -0.087 | 0.039 | 0.254 | 0.265 | 0.195 | 0.21 | 0.267 | 0.192 | 0.125 | 0.12 | 0.13 | 0.145 |
| Income Tax Expense
| -9.915 | 21.467 | 15.53 | 56.633 | 51.478 | 34.715 | 26.576 | 31.109 | 17.983 | 10.161 | 7.853 | 6.664 | 6.424 |
| Net Income
| -200.8 | -141.471 | 48.831 | 319.3 | 305.835 | 194.725 | 177.55 | 173.909 | 93.602 | 53.441 | 45.073 | 40.079 | 35.847 |
| Net Income Ratio
| -0.125 | -0.086 | 0.034 | 0.214 | 0.226 | 0.167 | 0.185 | 0.228 | 0.161 | 0.105 | 0.102 | 0.111 | 0.123 |
| EPS
| -0.37 | -0.26 | 0.09 | 0.7 | 0.71 | 0.46 | 0.42 | 0.42 | 0.3 | 0.17 | 0.14 | 0.14 | 0.39 |
| EPS Diluted
| -0.37 | -0.26 | 0.09 | 0.69 | 0.67 | 0.45 | 0.42 | 0.41 | 0.3 | 0.17 | 0.14 | 0.14 | 0.39 |
| EBITDA
| 23.717 | 111.625 | 181.738 | 479.956 | 470.211 | 315.363 | 260.997 | 251.042 | 158.723 | 97.112 | 79.411 | 66.109 | 41.588 |
| EBITDA Ratio
| 0.015 | 0.068 | 0.127 | 0.321 | 0.347 | 0.271 | 0.272 | 0.329 | 0.274 | 0.19 | 0.179 | 0.183 | 0.143 |